GHRP-2
Also known as: Growth Hormone Releasing Peptide-2
limited human dataWADA bannedNot FDA approvedResearch only
Published Dose Range
No published dosing data available.
Published Cycle Range
Short8 wks
Typical10 wks
Long12 wks
8-12 weeks. Lower-frequency maintenance possible.
Administration
Routessubcutaneous
Frequency1-3x daily
Safety Profile
Common side effects
- • Water retention
- • Appetite increase
- • Prolactin elevation
- • Cortisol elevation
Serious risks
- • Prolactin/cortisol elevation distinguishes from Ipamorelin
Requires monitoring
- • Prolactin
- • Cortisol
Pregnancy / breastfeeding
No data — consult clinician
Common Misconceptions
- Unlike Ipamorelin, GHRP-2 DOES elevate cortisol and prolactin
Commonly Stacked With
CJC-1295IpamorelinMK-677
Next Steps
Sign in to calculate your dose, add this compound to your stack, and check for interactions with your current cabinet.